-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Coya Therapeutics, Inc.'s Quiet Period Set To End on February 7th (NASDAQ:COYA)
Coya Therapeutics, Inc.'s Quiet Period Set To End on February 7th (NASDAQ:COYA)
Coya Therapeutics' (NASDAQ:COYA – Get Rating) quiet period is set to end on Tuesday, February 7th. Coya Therapeutics had issued 3,050,000 shares in its IPO on December 29th. The total size of the offering was $15,250,000 based on an initial share price of $5.00. During Coya Therapeutics' quiet period, insiders and underwriters that worked on the IPO are restricted from issuing any research reports for the company because of regulations issued by the Securities and Exchange Commission. Following the end of the company's quiet period, the brokerages that served as underwriters will likely initiate research coverage on the company.
Analyst Upgrades and Downgrades
Separately, Chardan Capital initiated coverage on shares of Coya Therapeutics in a report on Thursday, January 26th. They issued a "buy" rating and a $9.00 price target on the stock.
Get Coya Therapeutics alerts:Coya Therapeutics Stock Down 4.2 %
NASDAQ COYA opened at $4.35 on Tuesday. Coya Therapeutics has a 12 month low of $4.26 and a 12 month high of $5.67.
About Coya Therapeutics
(Get Rating)Coya Therapeutics Inc is a clinical-stage biotechnology company. It involved in developing proprietary treatments focused on the biology and potential therapeutic advantages of regulatory T cells to target systemic inflammation and neuroinflammation. The company's therapeutic platforms include Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.
See Also
- Get a free copy of the StockNews.com research report on Coya Therapeutics (COYA)
- Why Gold Can Be A Glistening Addition To Your Portfolio Right Now
- SoFi Technologies Smashes Earnings but Beware the Fed Decision
- Buying The Dip In Colgate-Palmolive
- Mullen Automotive On Hiring Spree, What Could That Mean?
- InterDigital Raises Its Earnings Guidance
Receive News & Ratings for Coya Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coya Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
Coya Therapeutics' (NASDAQ:COYA – Get Rating) quiet period is set to end on Tuesday, February 7th. Coya Therapeutics had issued 3,050,000 shares in its IPO on December 29th. The total size of the offering was $15,250,000 based on an initial share price of $5.00. During Coya Therapeutics' quiet period, insiders and underwriters that worked on the IPO are restricted from issuing any research reports for the company because of regulations issued by the Securities and Exchange Commission. Following the end of the company's quiet period, the brokerages that served as underwriters will likely initiate research coverage on the company.
Coya Therapeutics(納斯達克股票代碼:COYA — 獲取評級)的平靜期定於2月7日星期二結束。Coya Therapeutics在12月29日的首次公開募股中發行了305萬股股票。根據5.00美元的初始股價,此次發行的總規模爲15,250,000美元。在Coya Therapeutics的平靜期,由於美國證券交易委員會發布的規定,參與首次公開募股的內部人士和承銷商被限制爲該公司發佈任何研究報告。在該公司的平靜期結束後,擔任承銷商的經紀公司可能會啓動對該公司的研究報道。
Analyst Upgrades and Downgrades
分析師升級和降級
Separately, Chardan Capital initiated coverage on shares of Coya Therapeutics in a report on Thursday, January 26th. They issued a "buy" rating and a $9.00 price target on the stock.
另外,Chardan Capital在1月26日星期四的一份報告中開始對Coya Therapeutics的股票進行報道。他們對該股發佈了 “買入” 評級和9.00美元的目標股價。
Coya Therapeutics Stock Down 4.2 %
Coya Therapeutics 股票下跌 4.2
NASDAQ COYA opened at $4.35 on Tuesday. Coya Therapeutics has a 12 month low of $4.26 and a 12 month high of $5.67.
納斯達克COYA週二開盤價爲4.35美元。Coya Therapeutics創下12個月低點4.26美元,創12個月高點5.67美元。
About Coya Therapeutics
關於 Coya Therapeut
Coya Therapeutics Inc is a clinical-stage biotechnology company. It involved in developing proprietary treatments focused on the biology and potential therapeutic advantages of regulatory T cells to target systemic inflammation and neuroinflammation. The company's therapeutic platforms include Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.
Coya Therapeutics Inc是一家處於臨床階段的生物技術公司。它參與開發專有治療方法,側重於靶向系統性炎症和神經炎症的調節性T細胞的生物學和潛在治療優勢。該公司的治療平臺包括增強TreG的生物製劑、Treg衍生的外泌體和自體調節性Treg細胞療法。
See Also
另見
- Get a free copy of the StockNews.com research report on Coya Therapeutics (COYA)
- Why Gold Can Be A Glistening Addition To Your Portfolio Right Now
- SoFi Technologies Smashes Earnings but Beware the Fed Decision
- Buying The Dip In Colgate-Palmolive
- Mullen Automotive On Hiring Spree, What Could That Mean?
- InterDigital Raises Its Earnings Guidance
- 免費獲取 StockNews.com 關於 Coya Therapeutics(COYA)的研究報告的副本
- 爲甚麼黃金現在可以成爲你投資組合的閃亮補充
- SoFi Technologies 打破收益但要當心美聯儲
- 買入 Colgate-Palmolive 的 Dip
- Mullen Automotive 正在瘋狂招聘,那可能意味着甚麼?
- InterDigital 上調了收益預期
Receive News & Ratings for Coya Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coya Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接收Coya Therapeutics每日的新聞和收視率 -在下面輸入您的電子郵件地址,通過Marketbeat.com的免費每日電子郵件時事通訊接收Coya Therapeutics及相關公司最新新聞和分析師評級的簡明每日摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧